

**Original article:**

**TESTING CHEMICAL CARCINOGENICITY BY USING  
A TRANSCRIPTOMICS HEPARG-BASED MODEL?**

Tatyana Y. Doktorova<sup>\*1‡</sup>, Reha Yildirimman<sup>\*2</sup>, Liesbeth Ceelen<sup>3</sup>, Mireia Vilardell<sup>2</sup>, Tamara Vanhaecke<sup>1</sup>, Mathieu Vinken<sup>1</sup>, Gamze Ates<sup>1</sup>, Anja Heymans<sup>1</sup>, Hans Gmuender<sup>4</sup>, Roque Bort<sup>5,6</sup>, Raffaella Corvi<sup>7</sup>, Pascal Phrakonkham<sup>7</sup>, Ruoya Li<sup>8</sup>, Nicolas Mouchet<sup>9</sup>, Christophe Chesne<sup>8</sup>, Joost van Delft<sup>10</sup>, Jos Kleinjans<sup>10</sup>, Jose Castell<sup>5,6</sup>, Ralf Herwig<sup>2\*\*</sup>, Vera Rogiers<sup>1\*\*</sup>

<sup>1</sup> Department of Toxicology, Center for Pharmaceutical Research, Vrije Universiteit Brussel, 1090, Brussels, Belgium

<sup>2</sup> Max Planck Institute for Molecular Genetics, Department Vertebrate Genomics, D-14195 Berlin, Germany

<sup>3</sup> Pathlicon, 9940, Evergem, Belgium

<sup>4</sup> Genedata AG, 4053, Basel, Switzerland

<sup>5</sup> Unit of Experimental Hepathology, University Hospital La Fe Valencia, Spain

<sup>6</sup> University of Valencia, Faculty of Medicine, Department of Biochemistry and Molecular Biology, E-46009, Valencia, Spain

<sup>7</sup> European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Systems Toxicology Unit, 21027, Ispra, Italy

<sup>8</sup> Biopredic International, 35000, Rennes, France

<sup>9</sup> Institut Génétique et Développement de Rennes, 6290, Rennes, France

<sup>10</sup> Department of Toxicogenomics, Maastricht University, 6229 ER, Maastricht, The Netherlands

Equally contributed as \*first and \*\*last authors.

‡ Corresponding author: T. Y. Doktorova, Vrije Universiteit Brussel, Department of Toxicology, Center for Pharmaceutical Research, Laarbeeklaan 103, B-1090, Brussels, Belgium; Tel: +3224774507; Fax: +3224774582; E-mail: [tadoktor@vub.ac.be](mailto:tadoktor@vub.ac.be).

**ABSTRACT**

The EU FP6 project carcinoGENOMICS explored the combination of toxicogenomics and *in vitro* cell culture models for identifying organotypical genotoxic- and non-genotoxic carcinogen-specific gene signatures. Here the performance of its gene classifier, derived from exposure of metabolically competent human HepaRG cells to prototypical non-carcinogens (10 compounds) and hepatocarcinogens (20 compounds), is reported. Analysis of the data at the gene and the pathway level by using independent biostatistical approaches showed a distinct separation of genotoxic from non-genotoxic hepatocarcinogens and non-carcinogens (up to 88 % correct prediction). The most characteristic pathway responding to genotoxic exposure was DNA damage. Interlaboratory reproducibility was assessed by blindly testing of three compounds, from the set of 30 compounds, by three independent laboratories. Subsequent classification of these compounds resulted in correct prediction of the genotoxicants. As expected, results on the non-genotoxic carcinogens and the non-carcinogens were less predictive. In conclusion, the combination of transcriptomics with the HepaRG *in vitro* cell model provides a potential weight of evidence approach for the evaluation of the genotoxic potential of chemical substances.

**Keywords:** genotoxic carcinogens, non-genotoxic carcinogens, gene expression profiling, pathways-based analysis, HepaRG cell line, liver-based *in vitro* models

## INTRODUCTION

Exposure to potential human carcinogens and possible subsequent occurrence of cancer is of major concern for the safety of man and his environment. For decades, the 2-year rodent carcinogenicity assay has been the ultimate model for evaluating the carcinogenic potential of substances (EU, 1988). In general, this test is indicated by positive results obtained in an *in vitro* screening battery, usually followed by subsequent positive *in vivo* follow-up genotoxicity tests. The 2-year carcinogenicity assay, however, has several scientific drawbacks as the tested doses are unrealistically high and important interspecies differences exist, thus questioning human relevance of data obtained. Indeed, a substantial number of false positive results (*i.e.* identified as carcinogens in the rodent cancer bioassay but actually proven non-carcinogens for humans) are generated (Ennever et al., 1987; Gold and Slone, 1993). Furthermore, ethical and economic obstacles relate to the use of large numbers of animals, high doses and long duration times, and large costs (Ferdowsian and Beck, 2011; Doktorova et al., 2012). Furthermore, regulatory requirements for *in vivo* testing of various compounds differ substantially worldwide. In Europe, for example, *in vivo* testing of cosmetic products and their ingredients is prohibited because of the implementation in Directive 76/768/EC of strict testing and marketing bans. Both have been taken over in the actual cosmetic Regulation 1223/2009 (EU, 2009). Exemptions can only be claimed when the tested compound is equally in use in other consumer and industrial products for which animal testing may be necessary to ensure compliance with the legal frameworks applicable to these products (EC, 2013) *e.g.* cosmetic products are generally also subject to the horizontal REACH (Registration, Evaluation, Authorization and restriction of Chemicals) re-

quirements, which impose testing of a large amount of chemicals. Although only for high production volume chemicals carcinogenicity testing is required, and this still will involve a large number of animals (SCCP, 2006). Therefore, the development of assays/strategies able to identify carcinogens in a shorter timeframe, at a lower cost and preferably not using animals presents a huge challenge. Different approaches have been proposed, among which the use of genetically modified animals, the incorporation of histopathological data derived from repeated-dose toxicity studies, and toxicogenomics as an endpoint combined with *in vivo* treatment or *in vitro* cell culture exposure (Bercu et al., 2010; Doktorova et al., 2012; Magkoufopoulou et al., 2012). A toxicogenomics approach allows investigation of the entire genome response to toxicant effects and is an acknowledged strategy for discovering the mode of action of compounds and for identifying potential biomarkers of exposure and toxicity. It also allows to quantify and validate biomarker signatures (Bercu et al., 2010; Van Hummelen and Sasaki, 2010; Waters et al., 2010).

In this respect, the recently ended EU framework 6 project, carcinoGENOMICS ([www.carcinogenomics.eu](http://www.carcinogenomics.eu)), had as final goal the development of an organ-specific battery of mechanism-based *in vitro* tests, accounting for various modes of carcinogenic action, using "omics" technologies coupled with *in vitro* cell systems from rat and human origin (Vinken et al., 2008). The project was conveyed in two phases and during the first one (Phase I) the best performing liver-, kidney- and lung-derived *in vitro* models were selected mostly based on "omics" responses generated from a well-defined set of 15 model compounds causing genotoxicity and carcinogenicity (Doktorova et al., 2013) (Table 1). The choice of the compounds was based on several strict criteria including di-

versity and selectivity, biochemical and biophysical properties, and availability of toxicological information (Vinken et al., 2008). With regard to the liver-based *in vitro* models, which were used to evaluate the 15 prototypical compounds, the human hepatoma cell line HepaRG generated the best performing gene classifier, differentiating DNA-reactive from DNA non-reactive mechanisms (Doktorova et al., 2013). In the second phase of the project (Phase II), an additional number of 15 carefully selected compounds (thus resulting in a total of 30 analyzed compounds, shown in Table 1) were tested using HepaRG cells. The chemical selection for the second phase of the project was mostly focused on human relevance, e.g. whether the compounds are known human carcinogens. The global study results are reported here, including the classification performance and assessment of the interlaboratory reproducibility in three independent laboratories of three blindly tested compounds: as a prototypical genotoxic (GTX) carcinogen Benzo(a)pyrene was used, as a non-genotoxic (NGTX) carcinogen Tetradecanoyl phorbol acetate and as a non-carcinogen (NC) Clonidine hydrochloride were used, respectively.

## MATERIALS AND METHODS

### *Compounds, cell culture and treatment*

For the *in vitro* experiments which were aiming at enrichment of the classifier, human hepatoma-derived HepaRG cells (Biopredic International, France) were cultivated as previously described (Gripon et al., 2002; Guillouzo et al., 2007). At day 13 of cultivation, dimethylsulfoxide (DMSO)-containing medium was added for 7 days (Gripon et al., 2002). At day 19, using the same study conditions as applied during the first phase of the project (Doktorova et al., 2013), the cells were exposed for 72 h to the second set of 15 prototypical compounds chosen during the second phase of the project, i.e. 5 GTX (N-nitrosomorpholine, NMP; Hydroquinone, HQO; Hydrazine dihydrochloride, HHC; 2-

acetylaminofluorene, TAF; 2-amino-3-methylimidazo(4,5-f)quinoline, AMQ), 5 NGTX (Fumonisin B1, FMB; Cyclosporine A, CsA; Acetamide, ACE; Diethylhexyl Phthalate, DHP; Ethanol, ETH), 5 NC (4-acetylaminofluorene, FAF; D,L-Menthol, DLM; Benzoin, BEN; Benzyl Alcohol, BEA; Triclosan, TRI). IC10 concentrations (reducing cell viability by 10 %) were determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (MTT test) (see Table 1) (number of replicates n = 3) (Mosmann, 1983) following 72 h incubation with the selected chemicals. Further exposure to the IC10 concentrations was initiated and RNA samples were collected at 24 h and 72 h. Technical and experimental specifications are presented in Table 1.

For the interlaboratory reproducibility study coordinated by the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), three compounds from the Phase I list of chemicals were blindly labelled as D (Benzo(a)pyrene), E (Clonidine hydrochloride), F (Tetradecanoyl phorbol acetate) (EURL ECVAM), distributed (Maastricht University) and independently tested in three laboratories (Vrije Universiteit Brussel (VUB), Belgium; University Hospital of Valencia (HUL), Spain; Biopredic International (BPI), France). Each laboratory had to determine the IC10 concentrations by a MTT test and to expose at the selected doses for 24 h or 72 h. The experiments were executed according to a standard operating procedure distributed to the participating laboratories prior to the start of the experiments. The laboratories involved also attended an experimental training session organized by the Consortium. Maastricht University generated all microarray data and Genedata and Max Plank Institute performed all the data analyses. Technical and experimental specifications for the interlaboratory study are present in Table 2.

**Table 1:** IC10 concentrations of the 30 compounds (10 GTX, 10 NGTX and 10 NC) used in both phases of the carcinoGENOMICS project. The compounds were either dissolved in DMSO with 0.5 % v/v final concentration in the medium or in phosphate-buffered saline (\*). The experiments were performed in triplicate.

Toxicological category	Project Phase	Compounds	Abbreviated name	IC10
GTX	Project Phase 1	2-Nitrofluorene	2NF	18 µM
		Benzo[a]pyrene	BaP	5 µM
		Cyclophosphamide	CYCLO	700 µM
		Aflatoxine B1	AFB1	2,5 µM
		4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone	NNK	7500 µM
	Project Phase 2	N-nitrosomorpholine	NMP	0,216 mM
		Hydroquinone	HQO	0,15 mM
		Hydrazine dihydrochloride	HHC	0,860 mM
		2-acetylaminofluorene	TAF	0,0408 mM
		2-amino-3-methylimidazo(4,5-f)quinoline	AMQ	0,003 mM
NGTX	Project Phase 1	Methapyrilene hydrochloride	MPH	75 µM
		Piperonyl butoxide	PIPB	3,2 µM
		Tetradecanoyl Phorbol Acetate	TPA	35 µM
		Phenobarbital sodium	SPB	50 µM
		Wy-14643	WYE	210 µM
	Project Phase 2	Fumonisin B1	FMB	2,4 mM
		Cyclosporine A	CsA	0,0026 mM
		Acetamide	ACE	5,9 mM
		Diethylhexyl Phthalate	DHP	10 mM
		Ethanol	ETH	10 mM
NC	Project Phase 1	Clonidine	CND	0,1 µM
		Nifedipine	NIF	40 µM
		Tolbutamide	TOL	2000 µM
		Mannitol *	MAN	375 µM
		Diclofenac sodium *	SDF	50 µM
	Project Phase 2	4-acetylaminofluorene	FAF	0,22 mM
		D,L-Menthol	DLM	1,2 mM
		Benzoin	BEN	0,345 mM
		Benzyl Alcohol	BEA	6,5 mM
		Triclosan	TRI	0,022 mM

**Table 2:** IC10 concentrations of 3 blindly tested compounds (D, E, F) obtained by 3 different laboratories. The compounds were dissolved in DMSO with 0.5 % v/v final concentration. The experiments were performed in triplicate. (BPI, Biopredic International; HUL, University Hospital of Valencia; VUB, Vrije Universiteit Brussel)

Compounds	Laboratory	IC10	SD
D	BPI	0.0024 mg/ml	0.0015
	HUL	0.0044 mg/ml	
	VUB	0.0013 mg/ml	
E	BPI	0.7500 mg/ml	0.1767
	HUL	0.4850 mg/ml	
	VUB	0.4150 mg/ml	
F	BPI	0.0031 mg/ml	0.0027
	HUL	0.0084 mg/ml	
	VUB	0.0044 mg/ml	

### **Total RNA isolation**

Cell samples for RNA isolation were collected by removing cell culture media and adding lysis buffer (QIAshredder kit, Qiagen)(n = 3 for each compound). Total RNA extraction (RNA extraction kit, Qiagen), including a DNase digestion step, was done according to the manufacturer's instructions. Quality control was carried out by gel analysis using RNA 6000 Nano chips on an Agilent 2001 Bioanalyzer (RNA integrity number (RIN) > 7).

### **Microarray data hybridization**

Complementary RNA targets were prepared and hybridized according to the manufacturer's procedures on high-density oligonucleotide microarrays (*i.e.* Affymetrix U133 Plus 2.0 GeneChip). They were washed and stained using an Affymetrix fluidics station and subsequently scanned by means of an Affymetrix GeneArray scanner. Normalization quality controls, including scaling factors, average intensities, present calls, background intensities, noise and raw Q-values were within acceptable limits for all chips. Hybridization controls were identified on all chips and yielded the expected increases in intensities.

### **Microarray data re-annotation and normalization**

For the gene- and pathway-based analyses, the data of the 15 phase II compounds generated in this study were added to the previously obtained results of the 15 phase I chemicals. The raw microarray data were annotated to Ensembl version 61 genome and Gene Chip Robust Multi-array Average (GC-RMA) normalized. This resulted in 18,919 probe sets.

For classification analysis, the raw microarray data were annotated using the chip description files from Affymetrix and GC-RMA normalized. In order to eliminate batch effects, data from the different studies were half-z normalized (adjusting logarithmic expression values of transcripts within a group

in such a way that each transcript has a zero mean).

### **Microarray data analysis:**

#### **Enrichment of the existing gene classifier**

Gene as well as pathway level approaches were used to evaluate the global performance of the gene classifier composed of the 30 compounds tested during phase I and phase II of the project. For analysis at the gene level, the relative ratios (treatment *versus* control) were computed and a multivariate ANOVA analysis between the three groups (GTX carcinogens, NGTX carcinogens and NC) was applied. Only the top discriminative genes between the three groups selected after applying a *p*-value cut-off (0.01 or 0.05) were further selected for analysis. Hierarchical clustering analysis (HCA) (Euclidean Distance, Ward's Linkage) was performed to visualize the discriminative capacity of differentially expressed genes. Considering the direction of deregulation (*i.e.* up- or down-regulated), the genes were further assigned to biochemical and toxicological categories.

The second approach aimed at analyzing treatment-induced expression changes at the pathway level. First a response score ( $S_{ij}$ ) for each gene "*i*" in each treatment "*j*" was calculated as described previously (Yildirimman et al., 2011). Further *p*-values and fold changes were generated per gene "*i*" by comparing the average value of the intensity data of each treatment to the average of the respective control elements. These genes were further assigned to pathways using ConsensusPathDB (Kamburov et al., 2011; 2013). For the pathway response analysis, the response score for each pathway was defined as the average score derived from all  $S_{ij}$  within a certain pathway "*j*". In order to make the pathway response scores comparable across the experimental panel of compounds, relative pathway response (RPR) scores were calculated. This was done by dividing the individual scores for each experiment by the median pathway response score of that experiment. To identify pathways

discriminative between GTX, NGTX and NC, a multivariate ANOVA analysis was performed and the  $p$ -value was set at 0.01. PCA and HCA were performed to visualize the discriminative capacity of the selected pathways.

#### **Microarray data analysis: Classification analysis**

The Analyst module from the Genedata Expressionist<sup>®</sup> system was used for supervised classification analysis. Raw data from the Affymetrix arrays were assessed for quality and pre-processed using the Refiner Array module from the Genedata Expressionist<sup>®</sup> software package as follows. Defective areas, gradient and distortions on the arrays were diagnosed and expression values for all probe sets were obtained by applying the Gene Chip Robust Multi-array Average (GC-RMA) condensing method to the arrays. The Analyst module from the Genedata Expressionist<sup>®</sup> system was used for supervised classification analysis. A support vector machine was used for assessing the performance of classification (Cristianini and Shawe-Taylor, 2000). For SVM a linear kernel was used, and the penalty factor was set to 10. The kernel defines how the scalar product between two data points is evaluated, while the penalty factor determines how rigid the margin of the SVM classifier is. As a sampling method K-fold Cross Validation was used. For K-fold the number of folds was set to 10, and the number of repeats to 10. Categories for cross validation were GTX, NGTX and NC. Cross validation was performed using the GC-RMA and half-z normalized data.

#### **Interlaboratory reproducibility and compound prediction**

The interlaboratory reproducibility analysis was based on the comparison of the ranking of fold-changes (treatment *versus* control) per laboratory. Thus, the overlaps of the top 20, 50, 100, 200, 500, 1000, 2000, 5000, 10000, and 20000 ranked transcripts for each treatment/time group were deter-

mined. Random overlaps were determined as number of top ranked expression values divided by the number of transcripts on the microarray. Further, the area under the curve (AUC) for the top ranked transcripts (ranging from the 20<sup>th</sup> to the 5000<sup>th</sup> transcript) was estimated for all comparisons.

For the prediction of the three blinded compounds (D, E, F), two different kinds of data analysis were applied. The first approach was based on using SVM as classifier. Classification of the three blinded compounds was performed with the top 5000 ranked transcripts of the reference compendium (*i.e.* gene classifier composed of the 30 compounds from phases I and II) using the three toxic categories (GTX, NGTX, NC). In the second approach, a multivariate ANOVA argument was used. The total of 30 compounds, combined from phase I and II, were assigned to three classes, namely GTX, NGTX and NC. Every blinded compound (D, E or F) was consecutively assigned to each of the 3 classes and an ANOVA test was performed. Further, the number of significantly deregulated genes was computed ( $p = 0.05$ ). The blinded compounds were then assigned to the class with the largest number of significantly deregulated genes. A more detailed description of both bioinformatics approaches will be given in a separate manuscript (Herwig et al., in preparation).

## **RESULTS**

### **Analysis at the gene and pathway level**

At the gene level, the results of the ANOVA analysis showed that after 24 h and 72 h of exposure, 440 genes and 353 genes (Figure 1), respectively, were significantly deregulated. Most GTX carcinogens were separated from the NGTX carcinogens and NC, irrespective of the time of exposure. A survey of the involved pathways, however, revealed more carcinogen-specific processes after 72 h of exposure in comparison to 24 h of exposure. Briefly, the most prominent changes after 72 h of exposure consisted of upregulation of genes involved in apoptosis, DNA-repair and DNA damage (Figure 1).


Also increased oxidative stress, intra- and intercellular transport and metabolism were demonstrated. Downregulated genes were mostly involved in cellular metabolism and xenobiotic biotransformation, probably reflecting a dedifferentiation response as a result of GTX exposure. In comparison, after 24 h of exposure, these downregulated genes were associated with amino acid, carbohydrate and lipid metabolism, which may be interpreted as a dedifferentiation trigger, whereas the upregulated genes were involved in cell cycle progression, DNA replication, immunity and defense and oxidative stress. The latter may be explained as a cell cycle progression and general stress response. After 24 h of exposure, the DNA damage response appeared not yet activated.

Consequently for analysis at the pathway level, emphasis was laid on data generated from samples after 72h of exposure. The results showed that all GTX grouped together as such providing a better discrimination of GTX from NGTX and NC in comparison


with the results obtained at the gene level (Figure 2). A pre-selection with respect to the top 30 significant pathways showed that p53-dependent DNA damage was among the most affected and differentially expressed processes (Figure 3 A). In Figure 3 B, modulation of the p53 signaling pathway by the 30 prototypical compounds is presented as an example of a discriminative pathway. Further, similar to the results at the gene level, at the pathway level no separation was possible between NGTX carcinogens and NC.

### Classification analysis

After 72 h of exposure, the correct classification rate was slightly higher than after 24 h of exposure (Figure 4). Inclusion of the second set of 15 compounds (the phase II compounds) decreased this percentage. Finally, the lowest misclassification rate was observed when the data from both time-points were combined. The compounds most frequently wrongly classified, belonged to the NGTX and NC groups.



**Figure 1:** Hierarchical clustering analysis of **(A)** 440 genes and **(B)** the 353 genes following 24 and 72h of exposure that were significantly deregulated (False Discovery Rate  $\leq 0.05$ ) according to ANOVA analysis. The red color indicates upregulation of the genes whereas green downregulation.



**Figure 2:** (A) Principal component analysis and (B) hierarchical clustering analysis of the pathways that were significantly deregulated ( $p \leq 0.05$ ) according to ANOVA analysis following 72 h of exposure. The red dots are the genotoxic (GTX) carcinogens, the blue dots are the non-genotoxic (NGTX) carcinogens and the green dots are the non-carcinogens (NC).

### Interlaboratory reproducibility and classification of the coded compounds

The last part of the analysis focused on the interlaboratory reproducibility among the three laboratories for the three blindly tested compounds (D, E and F) which were part of the original set of 30 compounds. The calculations, using AUC for the top ranked transcripts, showed overall interlaboratory reproducible results (Figure 5). Compounds D and E generated reproducible results with

AUC values above 20 %. The outcome of compound F exposure, especially after 72 h of exposure, was less reproducible.

The compound prediction was further performed by using two approaches. In the first one, SVM was applied as algorithm and compound D was by the three laboratories unequivocally classified at all time-points as a GTX carcinogen (Figure 6). Compounds E and F were classified as either NGTX or NC. The response was uniform among the three



laboratories confirming a good interlaboratory reproducibility.

When compound prediction was carried out using an ANOVA argument, compound D was unequivocally classified as GTX whereas compounds F and E could not be


classified (Figure 7). In the figure red indicates the highest probability of a compound to belong to a specific class (e.g. GTX, NGTX, NC), whereas green indicates the lowest probability that a compound could be classified in the respective group.

**A**

Pathway DB	p-value
Viral myocarditis - Homo sapiens (human)_KEGG	0.000134682
NGF-independant TRKA activation_Reactome	0.000527092
Neurotransmitter Release Cycle_Wikipathways	0.000565863
Host Interactions with Influenza Factors_Reactome	0.000673255
p53 signaling pathway_BioCarta	0.000730738
Activation of TRKA receptors_Reactome	0.000924122
Activation of Pro-Caspase 8_Reactome	0.000962617
Caspase-8 is formed from procaspase-8_Reactome	0.000962617
p53-Dependent G1 DNA Damage Response_Reactome	0.001014222
p53-Dependent G1/S DNA damage checkpoint_Reactome	0.001014222
ABCA transporters in lipid homeostasis_Reactome	0.001236595
adp-ribosylation factor_BioCarta	0.001579303
visceral fat deposits and the metabolic syndrome_BioCarta	0.001620053
a6b1 and a6b4 Integrin signaling_PID	0.00165208
Phagosome - Homo sapiens (human)_KEGG	0.00232921
FasL/ CD95L signaling_Reactome	0.002758192
btg family proteins and cell cycle regulation_BioCarta	0.003192219
G1/S DNA Damage Checkpoints_Reactome	0.003459741
Vpu mediated degradation of CD4_Reactome	0.003709269
DNA damage response (only ATM dependent)_Wikipathways	0.003740356
Cardiac muscle contraction - Homo sapiens (human)_KEGG	0.003988059
Post-translational modification: synthesis of GPI-anchored proteins_Reactome	0.004259263
DNA damage response_Wikipathways	0.004495517
Ick and fyn tyrosine kinases in initiation of tcr activation_BioCarta	0.004792906
Methotrexate Pathway_Pharmacokinetics_PharmGKB	0.005255696
role of mef2d in t-cell apoptosis_BioCarta	0.005279352
Glycerolipid Metabolism_SMPDB	0.005300144
Inactivation of Cdc42 and Rac_Reactome	0.005445704
Eicosanoid ligand-binding receptors_Reactome	0.005631668
Melanoma - Homo sapiens (human)_KEGG	0.006026816

**B**

**p53 signalling pathway**



**Figure 3:** Top discriminative pathways (A) A pre-selection with respect to the top 30 significant pathways. (B) The p53 signaling pathway as an example of a discriminative pathway.

Exposure concentrations and time of exposure	Number of experiments			% of correctly classified experiments		
	Phase I	Phase II	Phase I and II	Phase I	Phase II	Phase I and II
IC10 24h and 72h	96	90	186	94	81	88
IC10 24h	48	45	93	85	69	78
IC10 72h	48	45	93	88	74	79

**Figure 4:** Classification analysis -Percentages of correctly classified experiments following GC-RMA and half-z normalization are indicated. As an algorithm Support Vector Machine is used. The cross validation is performed with the samples generated after 24h and 72h of exposure, separately or pooled together. The compounds tested in phase I and II of the project are shown. The experiments were performed in triplicate. (IC10, inhibitory concentration 10 %)

	HUL D 72h	VUB D 72h	BPI D 72h		HUL D 24h	VUB D 24h	BPI D 24h
BPI D 72h	35.6%	23.6%		BPI D 24h	22.7%	21.7%	
VUB D 72h			23.7%	VUB D 24h			21.6%
	HUL E 72h	VUB E 72h	BPI E 72h		HUL E 24h	VUB E 24h	BPI E 24h
BPI E 72h	29.5%	23.6%		BPI E 24h	26.3%	20.2%	
VUB E 72h			25.7%	VUB E 24h			21.3%
	HUL F 72h	VUB F 72h	BPI F 72h		HUL F 24h	VUB F 24h	BPI F 24h
BPI F 72h	19.8%	19.7%		BPI F 24h	26.0%	35.2%	
VUB F 72h			20.6%	VUB F 24h			27.6%

**Figure 5:** Interlaboratory reproducibility - Results among three laboratories of three blindly tested compounds denoted as D, E and F using Area Under the Curve for the top ranked transcripts. Darker green indicates higher reproducibility of results among the compared laboratories. (BPI, Biopredic International; HUL, University Hospital of Valencia; VUB, Vrije Universiteit Brussel)

Tested compound	Treatment time	Laboratory	Probability of classification			
			DMSO	GTX	NGTX	NC
D	24h	BPI	-1.70	1.00	-2.28	-0.28
			-1.60	1.24	-1.54	-0.80
		HUL	-1.26	1.08	-1.81	-0.83
			-1.25	1.28	-1.52	-1.40
		VUB	-1.31	0.99	-1.88	-0.66
			-1.39	1.17	-1.86	-0.63
	72h	BPI	-1.55	1.17	-1.92	-0.45
			-1.33	0.60	-1.35	-0.92
		HUL	-1.30	1.81	-1.60	-1.06
			-2.23	2.99	-2.13	-1.03
		VUB	-1.71	2.69	-1.88	-1.47
			-2.07	3.34	-2.01	-1.77
E	24h	BPI	-3.35	-0.43	-0.01	0.38
			-0.87	-1.12	-0.48	-0.04
		HUL	-1.78	-0.77	0.78	-0.88
			-1.74	-1.19	0.58	-0.22
		VUB	-2.49	-1.33	1.18	-0.18
			-1.20	-1.50	-0.36	0.48
	72h	BPI	-2.15	-0.76	0.31	-0.42
			-1.45	-1.23	0.86	-0.54
		HUL	-3.12	-1.26	-0.32	-0.53
			-2.69	-1.04	0.27	0.13
		VUB	-3.00	-0.61	-0.24	-0.37
			-3.02	-1.03	0.88	-0.20
F	24h	BPI	-2.36	-0.79	0.56	0.78
			-1.55	-1.04	1.14	-0.55
		HUL	-1.51	-0.97	0.88	-0.64
			-1.14	-1.24	0.34	-0.11
		VUB	-1.29	-1.48	0.43	0.16
			-1.42	-0.79	0.48	-0.35
	72h	BPI	-2.20	-0.16	0.53	-0.36
			-1.93	-0.11	0.85	-1.00
		HUL	-2.07	-0.12	0.23	-0.80
			-0.39	-1.67	-0.58	0.38
		VUB	0.13	-1.43	-0.01	-0.63
			0.34	-1.13	0.14	-0.84

**Figure 6:** Interlaboratory reproducibility - The results obtained among three laboratories of three blindly tested compounds (denoted as D, E and F) using Support Vector Machine as algorithm, are presented. Red indicates the highest probability of a compound to belong to a specific class (e.g. DMSO control, GTX, NGTX, NC), whereas green indicates the lowest probability that a compound could be classified in the respective group. The experiments were performed in triplicate. (BPI, Biopredic International; HUL, University Hospital of Valencia; VUB, Vrije Universiteit Brussel)

Compound	Test laboratories	GTX	NGTX	NC
D	BPI	4669	3383	3239
	HUL	4835	3071	2749
	VUB	4405	3748	3670
E	BPI	4007	3532	3523
	HUL	4275	3702	3569
	VUB	3921	3944	3965
F	BPI	3888	4077	4069
	HUL	3834	4120	4038
	VUB	3656	4076	4160

**Figure 7:** Interlaboratory reproducibility

Results among three laboratories of three blindly tested compounds denoted as D, E and F using ANOVA approach. Red indicates the highest probability of a compound to belong to a specific class (e.g. GTX, NGTX, NC), whereas green indicates the lowest probability that a compound could be classified in the respective group. The experiments were performed in triplicate. (BPI, Biopredic International; GTX, genotoxic; HUL, University Hospital of Valencia; NC, non-carcinogens; NGTX, non-genotoxic; VUB, Vrije Universiteit Brussel)

## DISCUSSION

The ability of a chemical to induce cancer is traditionally assessed by a 2-year rodent carcinogenicity assay. Although this assay is far from ideal, for the time being it is the most commonly used model for human cancer risk assessment (EU, 2008). Approaches to at least partially substitute the necessity for *in vivo* testing are ongoing and among the different strategies proposed, toxicogenomics is a promising methodology (Benfenati et al., 2009; Bercu et al., 2010; Doktorova et al., 2012; Magkoufopoulou et al., 2012). Indeed, the combination of transcriptomics with short-term *in vivo* exposure has been proposed by several teams (Ellinger-Ziegelbauer et al., 2005; Nakayama et al., 2006; Ellinger-Ziegelbauer et al., 2008; Fielden et al., 2008; Uehara et al., 2008; Matsumoto et al., 2009; Doktorova et al., 2011). Majorly involved discriminative pathways are DNA damage, cell cycle progression, oxidative stress and detoxification response. Interpretation of transcriptomics data derived from *in vitro* exposure studies is even more challenging.

In the current study, the performance of the gene classifier generated following expo-

sure of HepaRG cells to 30 prototypical GTX, NGTX carcinogens and NC was assessed. The choice of the *in vitro* model was based on a previously performed study (Phase I of the project) in which the HepaRG model was chosen among 5 commonly-used liver-based *in vitro* models as the system able to generate the best discriminative gene classifier (Doktorova et al., 2013). The results shown here were generated to obtain a gene classifier based on a larger group of compounds as such covering more diverse mechanisms of action. After analyzing the global gene expression data of the 30 compounds by using several statistical approaches including cross validation and classification analysis, a slightly higher misclassification rate in comparison to the initial test set was observed. This could be attributed to the fact that inclusion of additional compounds diversified the pool of involved mechanisms of action and might as such have lead to a slightly lower correct prediction rate. On the other hand, diversification usually contributes to the generation of a more reliable gene classifier. Additionally, some difficulties associated with the selection of appropriate test compounds should be acknowledged, especially when human relevance is required. In-

terestingly, despite the slightly higher misclassification rate, DNA damage remains the most characteristic pathway after exposure of the cells to GTX carcinogens. Indeed, the normal reaction of cells upon disruption of DNA integrity following chemical exposure consists of the activation of a number of downstream targets including tumor suppressor p53 and murine double minute 2 (Mdm2) (Lu, 2010; Oliver et al., 2011). Further, the effect is transferred onto a number of target genes involved in cell cycle, apoptosis, DNA repair and several others associated with the maintenance of normal cellular homeostasis and response to stimuli (Ellinger-Ziegelbauer et al., 2005; Ellinger-Ziegelbauer et al., 2008). Indeed these genes were found deregulated following GTX insults by the majority of the selected compounds. This finding provides an opportunity for developing *in vitro* assays aimed at identifying genotoxicants in particular.

The second class of investigated chemicals consists of NGTX carcinogens. Unlike most GTX carcinogens, which directly or indirectly affect DNA, NGTX carcinogens do not bind to DNA, yet these substances can cause cancer in animal models and possibly also in humans (Hernandez et al., 2009). Indeed, in this study the tested NGTX carcinogens showed to act through various processes such as endocrine modification, immune suppression, inhibition of gap junction intercellular communication and apoptosis, epigenetic modifications, tissue-specific toxicity and general inflammatory/stress responses. Some of the GTX carcinogens as well as some NC, however, often induce these events. For example, TRI is classified in this study as a NC, but induces peroxisome proliferation, a feature typically attributed to NGTX carcinogens (Rodricks et al., 2010). Therefore, discrimination was possible mostly based on the GTX-specific pathways such as DNA damage. As NC, being predominantly liver toxicants, were equally involved in the above described processes, they clustered together with the NGTX.

It has to be pointed out, however, that the current separation of selected prototypical chemicals into classes is liable to change. An interesting example in this regards is FB1, which is currently classified as being NGTX, but the incubation of methanolic extracts of *Fusarium* cultures with DNA in the presence of rat liver S9 proteins results in the formation of DNA adducts (Bever et al., 2000). Therefore, the possibility exists that compounds present in *Fusarium* fungi might alkylate DNA and exert GTX properties (Bever et al., 2000). On the other hand, HQO is classified as a GTX according to our study as it shows genotoxicity or chromosomal aberrations in rodent bone marrow cells but evidence for any genotoxic effect *in vivo* is rather weak and the responses are only marginally positive (McGregor, 2007). Additionally, a NGTX mode of action of HQO is proposed that involves exacerbation of a spontaneously occurring rodent renal disease and chronic progressive nephropathy (McGregor, 2007). The misclassification of the compounds into the different toxic classes might be one of the causes for the slightly higher misclassification rate when the second set of chemicals has been added. Indeed, this set of compounds had a less clear-cut mechanism of action than the chemicals of the first part of the project. Also it remains difficult to discriminate between compounds that might share some mechanism of action *e.g.* GTX versus NGTX versus NC.

Apart from the classification performance of the HepaRG model (up to 88 % correct prediction), the transferability and reproducibility of the model among different laboratories were assessed. These parameters represent major steps in the validation of any test method. In this study, it was found that the interlaboratory reproducibility was situated within a range of 20-35 % overlap of the AUC of the top ranked transcripts. The most reproducible results among the three laboratories were those that were obtained after exposure to the GTX compound D. The classification exercise of the 3 coded compounds, when used as a validation set, re-

sulted in a high correct prediction rate for the GTX carcinogen. Indeed compound D was correctly identified as a GTX and recognized as BaP. The two other blinded compounds could not be predicted. These results were overall reproducible among the three laboratories.

In conclusion, the HepaRG model is a promising tool for identification of genotoxics. The assay, however, could not discriminate between NGTX carcinogens and NC and in its present form cannot be regarded as an alternative to carcinogenicity testing. Currently, the standard *in vitro* assays for the detection of genotoxics produce an unacceptably high number - up to 70 % and more - of irrelevant positive results (*i.e.* low specificity), meaning that compounds are *in vitro* identified as being genotoxics whereas *in vivo* they are not genotoxic (Kirkland et al., 2005; 2011; Kirkland and Fowler, 2010). This leads, for example in the case of candidate-pharmaceuticals, to follow-up confirmatory *in vitro* and *in vivo* genotoxicity testing which is not only expensive and consumes a lot of animals but it also slows down the development process of new chemical entities (Goodsaid et al., 2010). In the case of cosmetics, for which confirmatory *in vivo* tests are no longer possible in Europe as from July 2013 (EU, 2009), interesting compounds such as UV-filters and preservatives could erroneously be considered genotoxic, and thus restricted or even rejected (Ates et al., 2013). In such a case, identification of “not being a genotoxicant” as shown in this study, could be a valuable result to be added in a weight of evidence approach. However, in order to increase the reliability of this *in vitro* approach more reference compounds are needed in order to represent the high diversity of mechanisms involved in genotoxicity. This approach could in particular be of interest to be used in a tiered testing strategy to obtain additional mechanistic information. This type of strategy is under investigation by the pharmaceutical industry in the USA to de-risk false positive results obtained in standard genotoxicity testing batteries. Its

application is already under discussion with the US Food and Drug Administration (Goodsaid et al., 2010).

As shown in this study, genotoxics could be clearly identified using HepaRG cells as *in vitro* exposure model. A positive aspect of applying a toxicogenomics approach is the generation of detailed information on the mechanism of action of the tested compounds. In addition, the use of human-based cells also contributes to more reliable results since interspecies differences are avoided.

### DATA ACCESS

The microarray data is available at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=wtmfuemkddudnup&acc=GSE48990>

### FUNDING

The study was financially supported by the European 6th Framework Program carcinoGENOMICS (PL 037712).

### CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

### REFERENCES

- Ates G, Pauwels M, Doktorova T, Rogiers V. Retrospective analysis of the mutagenicity/genotoxicity data of the cosmetic ingredients present on the Annexes of the Cosmetic EU legislation (2000-12). *Mutagenesis* 2013;29:115-21.
- Benfenati E, Benigni R, Demarini DM, Helma C, Kirkland D, Martin TM et al. Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 2009;27:57-90.
- Bercu JP, Jolly RA, Flagella KM, Baker TK, Romero P, Stevens JL. Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens. *Regul Toxicol Pharmacol* 2010;58:369-81.
- Bever RJ Jr., Couch LH, Sutherland JB, Williams AJ, Beger RD, Churchwell MI et al. DNA adduct for-

- mation by *Fusarium* culture extracts: lack of role of fusarin C. *Chem Biol Interact* 2000;128:141-57.
- Cristianini N, Shawe-Taylor J. An introduction to support vector machines. Cambridge, UK: Cambridge Univ. Press, 2000.
- Doktorova T, Ellinger-Ziegelbauer H, Vinken M, Vanhaecke T, van Delft J, Kleinjans J et al. Comparison of hepatocarcinogen-induced gene expression profiles in conventional primary rat hepatocytes with in vivo rat liver. *Arch Toxicol* 2011;86:1399-411.
- Doktorova TY, Pauwels M, Vinken M, Vanhaecke T, Rogiers V. Opportunities for an alternative integrating testing strategy for carcinogen hazard assessment? *Crit Rev Toxicol* 2012;42:91-106.
- Doktorova TY, Yildirimman R, Vinken M, Vilardell M, Vanhaecke T, Gmuender H et al. Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models. *Carcinogenesis* 2013;34:1393-402.
- EC. Communication from the Commission to the European Parliament and the Council on the animal testing and marketing ban and on the state of play in relation to alternative methods in the field of cosmetics. Brussels: European Commission, 2013.
- Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. *Mutat Res* 2005;575:61-84.
- Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A, Ahr HJ. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. *Mutat Res* 2008;637:23-39.
- Ennever FK, Noonan TJ, Rosenkranz HS. The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. *Mutagenesis* 1987;2:73-8.
- EU. B.32. Carcinogenicity test. Commission Directive 88/302/EEC of 18 November 1987 adapting to technical progress for the ninth time Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. *Off J Eur Union* 1988;L133:37-42.
- EU. B.32 Carcinogenicity test. Council regulation (EU) No 440/2008 of 30 May laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH). *Off J Eur Union* 2008;L142: 338-43.
- EU. Regulation 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. *Off J Eur Union* 2009;L342:59-209.
- Ferdowsian HR, Beck N. Ethical and scientific considerations regarding animal testing and research. *PLoS One* 2011;6:e24059.
- Fielden MR, Nie A, McMillian M, Elangbam CS, Trela BA, Yang Y et al. Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. *Toxicol Sci* 2008;103:28-34.
- Gold LS, Slone TH. Prediction of carcinogenicity from two versus four sex-species groups in the carcinogenic potency database. *J Toxicol Environ Health* 1993;39:143-57.
- Goodsaid FM, Amur S, Aubrecht J, Burczynski ME, Carl K, Catalano J et al. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. *Nat Rev Drug Discov* 2010;9:435-45.
- Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I et al. Infection of a human hepatoma cell line by hepatitis B virus. *Proc Natl Acad Sci U S A* 2002;99:15655-60.
- Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. *Chem Biol Interact* 2007;168:66-73.
- Hernandez LG, van Steeg H, Luijten M, van Benthem J. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. *Mutat Res* 2009;682:94-109.
- Kamburov A, Pentchev K, Galicka H, Wierling C, Lehrach H, Herwig R. ConsensusPathDB: toward a more complete picture of cell biology. *Nucleic Acids Res* 2011;39:D712-7.
- Kamburov A, Stelzl U, Lehrach H, Herwig R. The ConsensusPathDB interaction database: 2013 update. *Nucleic Acids Res* 2013;41:D793-800.
- Kirkland D, Fowler P. Further analysis of Ames-negative rodent carcinogens that are only genotoxic in mammalian cells in vitro at concentrations exceeding 1 mM, including retesting of compounds of concern. *Mutagenesis* 2010;25:539-53.
- Kirkland D, Aardema M, Henderson L, Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. *Mutat Res* 2005;584:1-256.

- Kirkland D, Reeve L, Gatehouse D, Vanparys P. A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins. *Mutat Res* 2011;721:27-73.
- Lu X. Tied up in loops: positive and negative auto-regulation of p53. *Cold Spring Harbor Perspect Biol* 2010;2:a000984.
- Magkoufopoulou C, Claessen SM, Tsamou M, Jennen DG, Kleinjans JC, van Delft JH. A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. *Carcinogenesis* 2012;33:1421-9.
- Matsumoto H, Yakabe Y, Saito K, Sumida K, Sekijima M, Nakayama K et al. Discrimination of carcinogens by hepatic transcript profiling in rats following 28-day administration. *Cancer Inform* 2009;7:253-69.
- McGregor D. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. *Crit Rev Toxicol* 2007;37:887-914.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Meth* 1983;65:55-63.
- Nakayama K, Kawano Y, Kawakami Y, Moriwaki N, Sekijima M, Otsuka M et al. Differences in gene expression profiles in the liver between carcinogenic and non-carcinogenic isomers of compounds given to rats in a 28-day repeat-dose toxicity study. *Toxicol Appl Pharmacol* 2006;217:299-307.
- Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ et al. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. *Molecular Cell* 2011;43:57-71.
- Rodricks JV, Swenberg JA, Borzelleca JF, Maronpot RR, Shipp AM. Triclosan: a critical review of the experimental data and development of margins of safety for consumer products. *Crit Rev Toxicol* 2010;40:422-84.
- SCCP, Scientific Committee on Consumer Products. The SCCP'S notes of guidance for the testing of cosmetic ingredients and their safety evaluation. 6<sup>th</sup> rev., adopted by the SCCP during the 10th plenary meeting of 19th December 2006. SCCP, 2006.
- Uehara T, Hirode M, Ono A, Kiyosawa N, Omura K, Shimizu T et al. A toxicogenomics approach for early assessment of potential non-genotoxic hepatocarcinogenicity of chemicals in rats. *Toxicology* 2008;250:15-26.
- Van Hummelen P, Sasaki J. State-of-the-art genomics approaches in toxicology. *Mutat Res* 2010;705:165-71.
- Vinken M, Doktorova T, Ellinger-Ziegelbauer H, Ahr HJ, Lock E, Carmichael P et al. The carcino-GENOMICS project: critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays. *Mutat Res* 2008;659:202-10.
- Waters MD, Jackson M, Lea I. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. *Mutat Res* 2010;705:184-200.
- Yildirimman R, Brolen G, Vilardell M, Eriksson G, Synnergren J, Gmuender H et al. Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. *Toxicol Sci* 2011;124:278-90.

**Abbreviations:** 2NF, 2-nitrofluorene; ACE, acetamide; AFB1, aflatoxin B1; AMQ, 2-amino-3-methylimidazo(4,5-f)quinoline; AUC, area under the curve; BaP, benzo(a)pyrene; BEA, benzyl alcohol; BEN, benzoin; BPI, Biopredic; cDNA, complementary DNA; CND, clonidine; CsA, cyclosporine A; CYCLO, cyclophosphamide; DHP, diethylhexyl phthalate; DLM, D,L-menthol; DMSO, dimethylsulfoxide; ETH, ethanol; EURL ECVAM, European Union Reference Laboratory for Alternatives to Animal Testing; FAF, 4-acetylaminofluorene; FDR, false discovery rate; FMB, fumonisin B1; GC-RMA, gene chip robust multi-array average; GTX, genotoxic; HCA, hierarchical clustering analysis; HHC, hydrazine dihydrochloride; HQO, hydroquinone; HUL, University hospital of Valencia; IC10, inhibitory concentration reducing viability by 10 %; LOO, leave one out; MAN, D-mannitol; Mdm2, murine double minute 2; MPH, methapyrilene hydrochloride; MTT test, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test; NC, non-carcinogen; NGTX, non-genotoxic; NIF, nifedipine; NMP, N-nitrosomorpholine; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; PIPB, piperonylbutoxide; PBS, phosphate-buffered saline; PCA, principal component analysis; qRT-PCR, quantitative reverse transcription polymerase chain reaction; REACH, Registration, Evaluation, Authorization and restriction of Chemicals; RIN, RNA integrity number; RPR, relative pathway response; SDF, diclofenac sodium; SPB, phenobarbital sodium; SVM, support vector machine; TAF, 2-acetylaminofluorene; TOL, tolbutamide; TPA, tetradecanoyl phorbol acetate; TRI, triclosan; VUB, Vrije Universiteit Brussel; WYE, Wy-14643.